Microbiotica (Biotechnology, Health Care) — Funding, Investors & Signals 2026

Microbiotica

The microbiome is a new approach to medicine, offering potential for significant advancements. Microbiotica aims to remove translation challenges.

Founded 2016

Cambridge, United Kingdom 49 employees Series Unknown Total: $62.00M Biotechnology, Health Care +1

Microbiotica is a biotechnology company founded in 2016, headquartered in the United Kingdom. The company focuses on leveraging the microbiome as a novel approach to medicine, aiming to address translation challenges in the field. With a background rooted in a decade-long investment at the Wellcome Sanger Institute, Microbiotica boasts unparalleled capabilities in microbiome analysis linked to patient phenotype. They are considered a global leader in gut bacterial culturing, equipped with a world-leading microbiome Culture Collection, proprietary Reference Genome Database, and advanced microbiome bioinformatics. The company's strengths extend to the realm of microbiome/host biology and the preclinical development of bacterial products. Noteworthy is their pipeline of highly differentiated clinically-derived products, encompassing Live Bacterial Therapeutics and Biomarkers in areas such as IBD, Immuno-oncology, and Gut Epithelial Barrier Repair. Collaborations with prestigious entities like Cancer Research UK, Cambridge University Hospitals, Genentech/Roche, and the University of Adelaide underscore Microbiotica's commitment to forging impactful partnerships in advancing their initiatives. Their most recent milestone includes a Venture Round investment on 27th August 2024, with participation from notable investors such as Seventure Partners, IP Group, Cambridge Innovation Capital, British Patient Capital, Tencent, and Flerie Invest. The company's focus on harnessing the microbiome's potential in the medical landscape, coupled with strategic partnerships and robust investor support, positions Microbiotica as an intriguing player in the biotechnology and health care sectors.

Funding Stage	Amount	Investors	Lead Investors	Date
Venture Round	••••••	6	•••• ••••	27 Aug 2024
Series B	••••••	6	•••• ••••	07 Feb 2022
Venture Round	••••••	1		24 Oct 2018
Seed Round	••••••	2		19 Dec 2016

Funding Stage

Amount

Investors

Lead Investors

Date

Venture Round

••••••

•••• ••••

27 Aug 2024

Series B

••••••

•••• ••••

07 Feb 2022

Venture Round

••••••

24 Oct 2018

Seed Round

••••••

19 Dec 2016

FAQ About Microbiotica

The microbiome is a new approach to medicine, offering potential for significant advancements. Microbiotica aims to remove translation challenges.

Microbiotica was founded in 2016.

Microbiotica is headquartered in Cambridge, United Kingdom.

Microbiotica operates in the following industries: Biotechnology, Health Care, Health and Wellness.

Microbiotica has approximately 49 employees.

Microbiotica has completed 4 funding rounds, raising a total of $62.00M. The latest funding stage is Series Unknown.

Microbiotica offers: Development and commercialization of clinic-ready defined live biotherapeutic products for immuno-oncology and inflammatory bowel disease.

Top alternatives and competitors to Microbiotica include Scioto Biosciences, Inc, SFA Therapeutics, Microviable Therapeutics SL, ClostraBio, Inc, MaaT Pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Microbiotica and Scioto Biosciences, Inc are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Microbiotica

General Information

Track Microbiotica

Discover More

About Microbiotica

Services & Products

Target Customers

Funding Rounds & Investors (4)

Microbiotica Alternatives & Competitors

FAQ About Microbiotica

Don't just browse. Track.